Erschienen in:
01.02.2011 | Gynecologic Oncology
Dydrogesterone and other progestins in benign breast disease: an overview
verfasst von:
Adolf E. Schindler
Erschienen in:
Archives of Gynecology and Obstetrics
|
Ausgabe 2/2011
Einloggen, um Zugang zu erhalten
Abstract
Progestogens appear to have a dual effect on the cell cycle in breast cells and breast cancer cells. There is initially stimulation of mitotic activity. However, continuous application leads to cell apoptosis. This depends on type, dose and length of progestogen application in relation to estrogen action. In benign breast disease the use of progestogens results not only in reduction of mastodynia, but also a reduction in breast gland size and disappearance of nodularity proven by clinical examination and follow-up including breast ultrasound.